<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04690725</url>
  </required_header>
  <id_info>
    <org_study_id>PKUPH-sarcoma12</org_study_id>
    <nct_id>NCT04690725</nct_id>
  </id_info>
  <brief_title>TQB3525 for Advanced Bone Sarcomas With PI3KA Mutations or PTEN Loss</brief_title>
  <acronym>TQBSP</acronym>
  <official_title>Phase I Study of TQB3525, Phosphatidylinositol-3-Kinase α and δ Inhibitors, in Patients With Advanced Bone Sarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PI3K, protein kinase B (AKT), and mTOR signaling network promotes cell growth, survival,&#xD;
      metabolism, and motility, but becomes a critical oncogenic driver under aberrant conditions&#xD;
      that control the tumor microenvironment and angiogenesis. The PI3K-AKT-mTOR axis is the most&#xD;
      frequently deregulated signaling pathway in primary osteosarcoma and other bone tumors. PI3Ka&#xD;
      has high rates of 25-50% activating mutations associated with tumor formation in&#xD;
      osteosarcoma. Other causes of pathway hyperactivation include loss of function of the tumor&#xD;
      suppressor PTEN, gain-of-function mutations in AKT and PDK1, or upregulation of receptor&#xD;
      tyrosine kinases. TQB3525 is an orally bioavailable, potent, dual catalytic site inhibitor of&#xD;
      PI3Ka and PI3Kd. Tumor growth inhibition has been demonstrated in multiple xenograft&#xD;
      osteosarcoma models with PI3K-mutant, PTEN-null cell lines. The investigators try to&#xD;
      investigate TQB3525 in primary osteosarcoma and other bone tumors for its safety,&#xD;
      tolerability, dose-limiting toxicities (DLT), MTD and antitumor efficacy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>TQB3525 orally taken</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>toxicity profiles</measure>
    <time_frame>6 months</time_frame>
    <description>according to CTCAE 5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>6 months</time_frame>
    <description>from starting treatment to progression/death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>from starting treatment to death</description>
  </secondary_outcome>
  <other_outcome>
    <measure>fasting triglyceride</measure>
    <time_frame>6 months</time_frame>
    <description>dynamic changes from Peripheral Blood</description>
  </other_outcome>
  <other_outcome>
    <measure>fasting lipoprotein</measure>
    <time_frame>6 months</time_frame>
    <description>dynamic changes from Peripheral Blood</description>
  </other_outcome>
  <other_outcome>
    <measure>fasting insulin</measure>
    <time_frame>6 months</time_frame>
    <description>dynamic changes from Peripheral Blood</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">29</enrollment>
  <condition>Safety Issues</condition>
  <condition>Efficacy, Self</condition>
  <arm_group>
    <arm_group_label>TQB3525 arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3+3 design for phase I for RP2D (Recommended Phase 2 Dose) for adolescents (12-17 years old) (15mg QD or 20mg QD); phase II for efficacy exploration for another 17 patients using RP2D QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQB3525</intervention_name>
    <description>TQB3525 is an orally bioavailable, potent, class I kinase inhibitors of PI3Ka and PI3Kd.</description>
    <arm_group_label>TQB3525 arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  progression upon first-line chemotherapy;&#xD;
&#xD;
          -  with target lesions according to RECIST 1.1;&#xD;
&#xD;
          -  geno-profiling with PI3KA mutations or PTEN loss;&#xD;
&#xD;
          -  ECOG PS status 0 or 1 with a life expectancy &gt;3 months;&#xD;
&#xD;
          -  adequate renal, hepatic, and hematopoietic function;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  been previously exposed to other TKIs;&#xD;
&#xD;
          -  had central nervous system metastasis;&#xD;
&#xD;
          -  had other kinds of malignant tumors at the same time;&#xD;
&#xD;
          -  had cardiac insufficiency or arrhythmia;&#xD;
&#xD;
          -  had uncontrolled complications such as diabetes mellitus, coagulation disorders, urine&#xD;
             protein ≥ ++, and so on;&#xD;
&#xD;
          -  had pleural or peritoneal effusion that needed to be handled by surgical treatment;&#xD;
&#xD;
          -  had other infections or wounds;&#xD;
&#xD;
          -  pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Guo, Ph.D and M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Sarcoma Study Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University Shougang Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100036</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 25, 2020</study_first_submitted>
  <study_first_submitted_qc>December 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2020</study_first_posted>
  <last_update_submitted>December 29, 2020</last_update_submitted>
  <last_update_submitted_qc>December 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>GUO WEI</investigator_full_name>
    <investigator_title>Director, Head of Msculoskeletal Tumor Center</investigator_title>
  </responsible_party>
  <keyword>osteosarcoma</keyword>
  <keyword>ewing sarcoma</keyword>
  <keyword>chondrosarcoma</keyword>
  <keyword>PI3KA mutation</keyword>
  <keyword>PTEN loss</keyword>
  <keyword>TQB3525</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

